Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tim, volume pouring in 277 shares traded. Down 30%
So that was dated April of this year. Also looks like he exercised options?
Warrants and stock options are exercisable at exercise prices ranging from $0.30 per share to $1.00 per share, and expire five or ten years from the date of issuance.
Probably around the October time frame, unless the FDA reduces the amount of patients needed. Need roughly 20 more, then 28 days for trial, then data analysis...
This is crap today
Good to see you're still around.
I am a bit concerned with what tomorrow's CC will bring. Hopefully more great news, and not a delay in uplisting. That hasn't been mentioned in the last few proactive videos
I sure hope so. How are we 7% down on great news
No,
We completed a 350mg dose for HIV, there was also a 700mg dose subset.
Ya...it's on the OTC, it doesn't trade after hours.
The timing of their submission is suspect. I hopeful for P4 w/EUA. But fear that we will get P3. Also I don't believe they even did a study in M/M. I don't believe they have posted any data.
Question,
If Remdesivir gets approved, as they just submitted today. Then we won't get EUA as it's no longer an unmet need correct?
Has their drug been tested for the mild to moderate population, we know it only reduces hospital stay 4 days for severe/critical
Our times is coming
...right after Gileads drug is approved
https://www.reuters.com/article/us-health-coronavirus-gilead-sciences-re/gilead-seeks-us-approval-for-covid-19-treatment-remdesivir-idUSKCN2561WY
Houston: Doctors at a hospital here have used a new drug called RLF-100, also known as aviptadil, that has led to rapid recovery from respiratory failure in critically ill COVID-19 patients.
The drug has been approved by the FDA for emergency use at multiple clinical sites in patients who are too ill to enter the FDA's Phase 2/3 trials.
I agree, and I think the m/m is what needs to be tackled so it doesn't further advance. I've been reading articles about the post Covid people and what they are living with. We NEED to catch it early, and right now there isn't a better/ safer drug then Leronlimab. The FDA has literally nothing to lose as it is so safe.
Didn't the patients that were given Leronlimab in the eIND have a high viral load at the end stage of the virus?
Wouldn't the viral load be present and ramping up in the first phase of the virus? These patients are already showing symptoms, which would suggest they are advancing to the next stage of the virus.
Absolutely. I think if we are able to show a reduction in viral load, we have a winner, as those patients won't move on to the next phase. Team that up with the fact we are 64% safer than the placebo...I don't see how we can't get a p4 with EUA.
Considering the current SOC only reduces hospital stay by 4 days, doesn't reduce mortality or viral load (which I think is HUGE for us, especially in m/m patients) and has SAE's...I don't think that will be that hard.
I think with the safety profile being 64% better than placebo, the efficacy has to be there as well. We've seen viral load reduction in eIND patients. NP stated again there was a statistical significance and more. Dr J. in over 300 clinical trails hasn't seen results that Leronlimab was able to produce.
I would think we have to be better than the current SOC, which should get us EUA for m/m. I'm hoping once the FDA sees the complied data, and knowing that the S/C trails looked good, they will allow for earlier interim.
I hope we get the EUA for M/M trial.
I re-watched the DMSC proactive video they talk about CD10 quite a bit
Thanks Tom,
Always appreciated!
Tom,
What are your thoughts for this up coming week?
Yet another benefit to BP to partner/buyout.
Perfect example of why we need Leronlimab approved ASAP for use in M/M. Need to battle it early.
Mounting evidence suggests COVID-19 could cause brain damage in adults and kids
Again no mention of comment letter or update on uplisting. Hopefully we are still good to go in a few weeks.
Proactive video
I'm long in CYDY, haven't sold a share (wish I did at $10)
Seriously though
company, announced today it will submit requests for pre-submission meetings
I hope we are uplisted by then. Still nothing from the company regarding that comment letter.
By that rational we will see interim in mid Oct.
Nothing came of it, and we are struggling to get 195 S/C patients.
It's not Big Pharma, it's our own company putting out fluff pieces. Per today's PR, the company will submit a request to have a meeting...WTF is that, why did that need to be PR'd? PR that you had a meeting, and submitted data.
Last we heard something with the UK, we were a day or so away from signing, and starting trials, waiting on Ireland, then poof no word.
The company needs to start following through we need data, what is the date of our Type A meeting for the BLA?
While I enjoy these PR's
What happened to the original UK trial? We were a day or so away waiting for Ireland, then poof no word.
What is the update on our Type A meeting? Do we have a date scheduled?
Why not submit to a hot spot country like Mexico or Brazil, where there is a greater demand? It appears the UK is recording under a 1,000 cases a day, and around 50 deaths. Brazil is 50k+ cases and 1k+ deaths daily.
Ttgfp pop
Looks like Gilead is in trouble, market not counting on remdesivir and they are still looking to solidify the HIV market. Tick tock
I don't know why we aren't seeing Scott Kelly more. HE IS the CMO, HE should be speaking to the results and the significance. He is very well spoken and has a polished look. I very much want NP to be involved in the company, but we need a new front man.
Note the latest PR states engages, not that they have a new project manager, they talked to someone, so they engaged. Typical OTC scam talk.
Tim,
There is no vol, low share price, and no chatter on the board. Do the math.
Bronze! Hey we placed
Saltz,
I had also just assumed the placebo was a neutral material. If it is indeed the SOC Remdesvir or a combination, some get Remdesvir, some a neutral, then the numbers presented by NP 64% safer have WAY more significance. Whether we find out what the placebo was, is another question. Overall yesterday's news is very positive, who knows what's around the corner. When the M/M results are presented to the FDA, they may decide to take another look at the S/C trial data.